Kyverna Positive Phase 2 Readout: Deep Responses, But Very Small Sample (NASDAQ:KYTX)
Summary
Kyverna Therapeutics reported robust early Phase 2 miv-cel data in gMG, showing 100% response rates and deep, durable clinical improvements. Learn more about KY...
Description
Kyverna Therapeutics reported robust early Phase 2 miv-cel data in gMG, showing 100% response rates and deep, durable clinical improvements. Learn more about KY...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source